Paclitaxel-Carboplatin
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
... with paclitaxel/carboplatin treat- ment ( ~ 9 months; Table ...nab-paclitaxel/ carboplatin resulted in a significantly longer OS vs paclitaxel/ carboplatin (median, ...nab- ...
7
Original Article Efficacy, safety and tolerance of PEG-ENDO (an N-terminal mono-PEGylated recombinant human endostatin) with TC regimen ( paclitaxel/carboplatin) therapy in the treatment of advanced non-small cell lung cancer: a single-center, open trial phase I study
... Abstract: Purpose: The purpose of this study is to evaluate safety and tolerance of PEG-ENDO (an N-terminal mono- PEGylated recombinant human Endostatin) combined with TC (Paclitaxel/Carboplatin) in ...
7
Preoperative Conformal Radiotherapy Concurrently with Paclitaxel/Carboplatin in Gastric Cancer
... of carboplatin-paclitaxel with radiation therapy would result in a pathological CR rate, which will be in turn associated with OAS and DFS ben- ...with carboplatin-paclitaxel followed by ...
13
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer
... ACCEPTED MANUSCRIPT Prostacyclin Synthase, Thromboxane Synthase and Cancer combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small [r] ...
65
Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells
... of Paclitaxel and Gallic acid may be a promising protocol for treatment of cervical cancer and it could be a possi- ble replacement of the current commonly used regimen ...The Paclitaxel/Gallic acid combi- ...
13
Phase II/III weekly nab paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first line treatment of patients with metastatic triple negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
... nab-paclitaxel/ carboplatin in NSCLC, while matching the doses and schedule of the gemcitabine/carboplatin regimen evaluated in the TNBC phase II and III trials of iniparib and commonly used in ...
10
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
... arms: paclitaxel/carboplatin for 6 cycles maximum plus motesanib, continuously or intermittent orally, versus the same chemo- therapic regimen plus bevacizumab: motesanib continuously assumed plus ...
12
Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
... existing paclitaxel/carboplatin therapy in patients with stages III/IV CCC, whereas GOG0254 is a Phase II clinical study designed to examine the efficacy of the tyrosine kinase inhibitor sunitinib, which is ...
5
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
... of carboplatin AUC 7 followed by paclitaxel and gemcitabine is feasible as primary treatment for advanced ovarian cancer with 72% of patients being able to complete all the eight cycles of ...conventional ...
6
Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis
... “randomized paclitaxel carboplatin weekly 3 weeks ovarian cancer”; ...dense paclitaxel carboplatin weekly ovarian ...compared carboplatin plus weekly paclitaxel with standard ...
7
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
... A randomized phase 2 study of a human antiplatelet-derived growth factor a (PDGFR α ) mono- clonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin [r] ...
6
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
... Linifanib is a TKI that inhibits VEGFR1–3, PDGFR-b, c-Kit and FLT-3 [75]. A phase II study assessed linifanib monotherapy (two dose regimens) in a second-/third-line setting in 139 patients with advanced NSCLC; linifanib ...
13
Comparisons of the survival time of patients with ovarian cancer adopting post operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin
... Methods: Ninety-four patients were recruited for the study. These ovarian cancer patients were admitted into the Cancer Hospital Affiliated with Harbin Medical University for surgery from January 2008 to October 2009. ...
6
Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non Small Cell Lung Cancer
... the carboplatin plus gemcit- abine regimen in Japan was few compared to those of car- boplatin plus paclitaxel, almost all being reported from overseas ...plus carboplatin regi- men was allowed to ...
9
Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
... and carboplatin are the two most commonly used platinum-based ...development, carboplatin, was developed which was believed to have a milder side effect ...
6
jco.2014.57.0572.pdf
... compared carboplatin doses and schedules (AUC 6 every 3 weeks v AUC 2 once per week) concurrently with single-agent wP, but given results in other malignancies, the once-per- week regimen would likely cause less ...
11
Median Survival Time of Endometrial Cancer Patients with Lymphovascular Invasion at the Hospital Universiti Sains Malaysia
... of carboplatin and paclitaxel in patients with stage I–II endometrial cancer with high-intermediate- risk or high-risk features and with a median follow-up of 24 months showed no difference in overall ...
8
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
... to carboplatin-paclitaxel-bevacizumab or to carboplatin- paclitaxel versus carboplatin-paclitaxel-bevacizumab com- bination, a remarkable OS improvement was observed in patients ...
9
Targeting Angiogenesis for Treatment of Human Cancer
... for non‑small cell lung cancer in combination with carboplatin/ paclitaxel (CPM) or bevacizumab plus carboplatin/ paclitaxel (CPB) versus carboplatin/paclitaxel [46] TABLE 3: TYPES [r] ...
8
The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
... In our cohort, no patient had systolic orthostatic hypotension at baseline but five out of 26 patients developed this side effect at the 3–4 month assessment. Interestingly, at the 6–8 month evaluation, when the vast ...
6